Life Science Investing ANKTIVA® with BCG Demonstrates 96% Survival from Bladder Cancer at Three Years with Median Survival Not Yet Reached in BCG-Unresponsive High-Grade Papillary-Only Non-Muscle Invasive Bladder Cancer
Life Science Investing Driven by Strong Demand, ImmunityBio Reports 467% Year-to-Date Unit Growth and $75 Million in Sales Year-to-Date, Up 434% from Q3 2024
Life Science Investing FDA Tightens Survival Standards as Cancer Drug Pipeline Hits $866B Market Milestone
TomaGold Intercepts 6.68% ZnEq (1.57 g/t AuEq) over 48.05 Metres, including 39.03% ZnEq (9.15 g/t AuEq) over 2.90 Metres at Berrigan Mine and Identifies a Major Hydrothermal Footprint
Apollo Silver Announces Correction to Warrant Terms of $25 Million Strategic Investment by Eric Sprott and Jupiter Asset Management
